|
Allan Ferguson became a director of Biopure in April 2007. He brings to the board over 25 years of operating and management experience in engineering, manufacturing, and research and development, and 20 years of experience in international venture capital investing with life science and technology companies.
Ferguson is also a director of Autoimmune Inc., TransMedics Inc., Ulthera Inc., Xthetix Inc., and ZONARE Medical Systems. He recently retired as a senior partner of 3i's Venture Capital Group, where he headed up the firm's U.S. operation that he helped start. He previously served as a Biopure board member from December 1988 to December 1990, in connection with 3i's investment in the company.
Ferguson was formerly a managing partner of Aspen Ventures and a general partner of Atlas Ventures, where he helped establish Atlas' healthcare practice. He has also held senior operating positions at Johnson & Johnson, Ortho Diagnostics Systems Inc. and Damon Biotech, where he served as a managing director and senior vice president responsible for European operations.
Ferguson is a member of the New England Venture Capital Association (NEVCA) and the National Association of Corporate Directors (NACD), and was previously a board member of the National Venture Capital Association (NVCA). He holds a B.S. in chemical engineering from the University of Delaware and attended the Harvard Executive Management program. | 